MX2019006310A - Procedimiento para la preparacion de una formulacion de 2-[(3-aminopropil)amino]etanotiol liofilizado. - Google Patents

Procedimiento para la preparacion de una formulacion de 2-[(3-aminopropil)amino]etanotiol liofilizado.

Info

Publication number
MX2019006310A
MX2019006310A MX2019006310A MX2019006310A MX2019006310A MX 2019006310 A MX2019006310 A MX 2019006310A MX 2019006310 A MX2019006310 A MX 2019006310A MX 2019006310 A MX2019006310 A MX 2019006310A MX 2019006310 A MX2019006310 A MX 2019006310A
Authority
MX
Mexico
Prior art keywords
ethanethiol
aminopropyl
freeze
dried
preparation
Prior art date
Application number
MX2019006310A
Other languages
English (en)
Inventor
Wang-Zhang Xiuping
Pivette Perrine
Gonzalez Karine
Deutsch Eric
Clemenson Céline
Original Assignee
Clevexel Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clevexel Pharma filed Critical Clevexel Pharma
Publication of MX2019006310A publication Critical patent/MX2019006310A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/02—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a un procedimiento para la preparación de 2-[(3-aminopropil)amino]etanotiol liofilizado que comprende las siguientes etapas: a) la reacción de una solución de amifostina con un ácido fuerte, para obtener una solución de 2-[(3-aminopropil)amino]etanotiol, y b) la liofilización de la solución de 2-[(3-aminopropil)amino]etanotiol, con o sin adición de excipientes.
MX2019006310A 2016-11-30 2017-11-29 Procedimiento para la preparacion de una formulacion de 2-[(3-aminopropil)amino]etanotiol liofilizado. MX2019006310A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16306582.4A EP3330251A1 (en) 2016-11-30 2016-11-30 Process for the preparation of freeze-dried 2-[(3-aminopropyl)amino]ethanethiol
PCT/EP2017/080881 WO2018100008A1 (en) 2016-11-30 2017-11-29 Process for the preparation of freeze-dried 2-[(3-aminopropyl)amino]ethanethiol formulation

Publications (1)

Publication Number Publication Date
MX2019006310A true MX2019006310A (es) 2019-08-12

Family

ID=57542923

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006310A MX2019006310A (es) 2016-11-30 2017-11-29 Procedimiento para la preparacion de una formulacion de 2-[(3-aminopropil)amino]etanotiol liofilizado.

Country Status (11)

Country Link
US (1) US11021442B2 (es)
EP (2) EP3330251A1 (es)
JP (1) JP7138104B2 (es)
KR (1) KR102596798B1 (es)
CN (1) CN110300742B (es)
AU (1) AU2017369603B2 (es)
CA (1) CA3039425A1 (es)
IL (1) IL266811B (es)
MX (1) MX2019006310A (es)
WO (1) WO2018100008A1 (es)
ZA (1) ZA201902119B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824880A1 (en) * 2019-11-25 2021-05-26 Clevexel Pharma Freeze-dried powder containing 2-[(3-aminopropyl)amino]ethanethiol and its use for preparing a thermogel

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU670567A1 (ru) * 1978-02-06 1979-06-30 Предприятие П/Я В-2343 Способ получени дихлоргидрата бета-меркаптоэтил-1,3-пропилендиамина
US6239119B1 (en) 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
EP1343492B1 (en) * 2000-11-22 2006-02-01 Rxkinetix, Inc. Treatment of mucositis
JP2015515282A (ja) * 2012-04-25 2015-05-28 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 創傷治癒および組織修復のための組成物および方法
FR2994844B1 (fr) * 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris Formulation gelifiante a base de ketamine

Also Published As

Publication number Publication date
JP7138104B2 (ja) 2022-09-15
KR102596798B1 (ko) 2023-10-31
WO2018100008A1 (en) 2018-06-07
JP2019535801A (ja) 2019-12-12
AU2017369603A1 (en) 2019-05-02
IL266811B (en) 2021-10-31
AU2017369603B2 (en) 2021-04-29
IL266811A (en) 2019-07-31
US11021442B2 (en) 2021-06-01
BR112019011006A2 (pt) 2019-10-08
US20200239414A1 (en) 2020-07-30
EP3548464A1 (en) 2019-10-09
CN110300742B (zh) 2022-02-18
EP3330251A1 (en) 2018-06-06
ZA201902119B (en) 2023-01-25
CN110300742A (zh) 2019-10-01
BR112019011006A8 (pt) 2023-04-11
KR20190085526A (ko) 2019-07-18
CA3039425A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
PH12020550051A1 (en) Glp-1 compositions and uses thereof
WO2017070616A3 (en) Sexually transmitted disease vaccines
EA201890235A1 (ru) Стабилизированные растворимые f-полипептиды rsv до слияния
WO2015006555A3 (en) Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
PH12018501962A1 (en) Stablizied soluble pre-fusion rsv f proteins
EP3936141A3 (en) Anti-senescence compounds and uses thereof
MX2018007319A (es) Imidazoquinolinas pegiladas como agonistas tlr7 y tlr8.
MX347882B (es) Procedimiento mejorado para preparar (3e, 7e)-homofarnesol.
MX2018004938A (es) Vacunas de antigeno ligado a pcrv de p. aeruginosa.
EA201791537A1 (ru) Фармацевтическая композиция на основе наночастиц доцетаксела-альбумина, способ ее получения и ее применение
PH12017502323A1 (en) Novel xylanase
MX2020008125A (es) Composiciones que comprenden berberina.
WO2019078968A3 (en) Cyclic compounds as immunomodulating agents
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
WO2016020882A3 (en) Angiopoetin-like 4 (angptl4) antibodies and methods of use
MX2018006773A (es) Composiciones farmaceuticas que contienen doravirina, tenofovir disoproxil fumarato y lamivudina.
WO2016172269A3 (en) Insulin analogs having shortened b chain peptides and associated methods
MX346113B (es) Polimorfos de n-(2-metoxibenzoil)-4-[(metilaminocarbonil)amino]ben cenosulfonamida.
MX2019006310A (es) Procedimiento para la preparacion de una formulacion de 2-[(3-aminopropil)amino]etanotiol liofilizado.
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии
MX2019006122A (es) Metodo de hornear.
WO2018105941A3 (ko) 탈모방지 또는 발모촉진용 주사용 조성물
WO2018060962A3 (en) Metformin amino acid compounds and methods of using the same
WO2017093866A3 (en) An improved process for the preparation of indigo carmine
MX2017013480A (es) Composicion farmaceutica para tratar y/o prevenir el cancer.